Internship

Cell Line Development

Posted on 10/25/2024

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

No H1B Sponsorship

Framingham, MA, USA

Must be able to relocate to Framingham, MA and work 40 hours/week, Monday-Friday.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Currently pursuing a Bachelor's degree in Biological Engineering, Chemical Engineering, Biotechnology, Biology, or related field at an accredited college or university with the expectation that you will complete your current degree by the Spring of 2026
  • Must be enrolled in school the semester following your co-op with Sanofi.
  • Must be able to relocate to the office location and work 40hrs/week, Monday-Friday, for the full duration of the co-op
  • Must have permanent US work authorization
  • Strong technical background; including computer programming
  • Completed coursework in molecular biology, cell biology, and/or mammalian cell culture.
  • Excellent written and verbal communication, good organizational skills, and ability to think critically and work within a highly functional team environment
  • Lab experience in mammalian cell culture
  • Experience in laboratory automation
  • Experience in programming languages
Responsibilities
  • Assessment of automated cell line development processes
  • Clonal cell screening
  • Data analysis and communication
  • Experimental design

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse pipeline of new products. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • AI tool Muse accelerates patient recruitment, speeding up drug development.
  • Dupixent's EU approval opens new pediatric market segments.
  • Sanofi's investment in SureChill aligns with global sustainability trends.

What critics are saying

  • Competition in multiple myeloma market may impact Sarclisa's market share.
  • Regulatory challenges could delay rilzabrutinib's market entry.
  • Operational challenges may affect SureChill's scalability in Sub-Saharan Africa.

What makes Sanofi unique

  • Sanofi's Sarclisa shows significant benefits in multiple myeloma treatment.
  • Rilzabrutinib offers a first-in-class treatment for immune thrombocytopenia.
  • Dupixent is the first approved treatment for eosinophilic esophagitis in young children.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE